Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

Bortezomib inhibits nuclear factor-κB (NF-κB). Cetuximab is a chimeric mouse–human antibody targeted against epidermal growth factor receptor (EGFR). We hypothesised that concomitant blockade of NF-κB and EGFR signalling would overcome EGFR-mediated resistance to single-agent bortezomib and induce a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudek, A Z, Lesniewski-Kmak, K, Shehadeh, N J, Pandey, O N, Franklin, M, Kratzke, R A, Greeno, E W, Kumar, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694419/
https://www.ncbi.nlm.nih.gov/pubmed/19401697
http://dx.doi.org/10.1038/sj.bjc.6605043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694419/
https://www.ncbi.nlm.nih.gov/pubmed/19401697
http://dx.doi.org/10.1038/sj.bjc.6605043

Ejemplares similares